Bulletin
Investor Alert

June 9, 2020, 4:01 p.m. EDT

ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2020 Annual General Meeting held on June 9, 2020

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

(GLOBE NEWSWIRE via COMTEX) -- Geneva, Switzerland and Boston, MA - June 9, 2020 - ObsEva SA , a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that shareholders approved all Board proposals at its 2020 Annual General Meeting held on June 9, 2020.

The approved items are as follows:

- Shareholders approved the Annual Report, the Statutory Financial Statements and the Consolidated Financial Statements for Fiscal Year 2019

- Shareholders granted discharge to the Members of the Board of Directors and to the Executive Committee for year 2019

- Shareholders approved the proposed appropriation of the Financial Results for year 2019

- Shareholders approved the proposed re-elections to the Board of Directors and re-election of the Chairman of the Board of Directors

- Shareholders approved the proposed re-elections to the Compensation Committee

- Shareholders approved the re-election of PricewaterhouseCoopers SA as ObsEva SA's Auditors and Independent Registered Public Accounting Firm

- Shareholders approved the re-election of Perreard de Boccard SA as Independent Representative

- Shareholders approved the proposed compensation of the Board of Directors and the Executive Committee

- Shareholders approved the proposed increase of ObsEva SA's Authorized Share Capital

- Shareholders approved the proposed increase of ObsEva SA's Conditional Share Capital for Equity Plans

- Shareholders approved the proposed change to ObsEva SA's Equity Incentive Plan

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.